SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum DisorderPosted by On

The cannabis oil will be used as a part of the Companys proprietary SCI-210 treatment combination of CBD and CannAmide™

 TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of  the central nervous system, today announced it has signed an agreement with Israel’s leading and pioneer manufacturer and distributer of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE: TKUN), to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide™. SCI-210 treatment will be used in the Company’s clinical trial (“Trial”) on children with autism spectrum disorder (“ASD”).

The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit. The Company has already secured approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center to conduct the Company’s clinical trial.

The Trial will evaluate the safety, tolerability and efficacy of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, in comparison to CBD monotherapy in children with ASD. The study design is a 20-week, randomized double-blind…

Original Author Link click here to read complete story..


2023 | SPRC | IL0010951403andasBecannabiscbdcombinationInformationNewsofOilPartpress releaseSCISPARC stock exchangethetreatmentusedwill

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.